BIVI on Nasdaq
BIOVIE INC.
Price unavailable
Last updated Oct 16, 2026.
Overview
-$22.1MNet income, fiscal 20262
Financials
From the company’s reports to the SEC. Every number links to the filing it came from.
Key numbers, fiscal 2026
-214.9%Return on equity2
Financial statements
Every line of the income statement in the latest annual report, as filed.2
| Period ending | 2026-06-30 | 2025-06-30 |
|---|---|---|
| Amortization of intangible assets | $178.3K | $229.4K |
| Research and development expenses | $14.0M | $9.3M |
| General and administrative expenses | $8.5M | $8.6M |
| TOTAL OPERATING EXPENSES | $22.7M | $18.1M |
| LOSS FROM OPERATIONS | -$22.7M | -$18.1M |
| Change in fair value of derivative liabilities | -$3.8K | |
| Interest expense | $17.9K | $332.7K |
| Interest income | -$596.8K | -$853.0K |
| TOTAL OTHER INCOME, NET | -$578.9K | -$524.1K |
| NET LOSS | -$22.1M | -$17.5M |
| Deemed dividend related to ratchet adjustment to warrants | $43.5K | $369.5K |
| NET LOSS ATTRIBUTABLE TO COMMON STOCKHOLDERS | -$22.1M | -$17.9M |
| - Basic | -$3.05 | -$12.12 |
| - Diluted | -$3.05 | -$12.12 |
| - Basic | 7.2M shares | 1.5M shares |
| - Diluted | 7.2M shares | 1.5M shares |
Every line of the balance sheet in the latest annual report, as filed.2
| Period ending | 2026-06-30 | 2025-06-30 | 2024-09-30 |
|---|---|---|---|
| Cash and cash equivalents | $9.0M | $17.5M | |
| Grant receivable | $2.2M | $2.1M | |
| Prepaid and other current assets | $2.5M | $1.0M | |
| Total current assets | $13.6M | $20.7M | |
| Operating lease right-of-use asset, net | $262.6K | $339.7K | |
| Intangible assets, net | $178.3K | ||
| Goodwill | $345.7K | $345.7K | |
| TOTAL ASSETS | $14.3M | $21.6M | |
| Accounts payable and accrued expenses | $3.7M | $2.2M | |
| Current portion of operating lease liability | $91.0K | $74.5K | |
| Total current liabilities | $3.8M | $2.3M | |
| Operating lease liability, net of current portion | $184.4K | $275.4K | |
| TOTAL LIABILITIES | $4.0M | $2.6M | |
| Common stock, $0.0001 par value; 800,000,000 shares authorized at June 30, 2026 and June 30, 2025; 7,545,474 shares issued of which 7,542,638 shares outstanding at June 30, 2026; and 1,917,061 shares issued of which 1,914,224 shares are outstanding at June 30, 2025 | $754 | $192 | |
| Additional paid in capital | $384.5M | $371.2M | |
| Accumulated deficit | -$374.3M | -$352.1M | |
| Treasury stock | -$29 | -$29 | |
| Total stockholders' equity | $10.3M | $19.0M | |
| TOTAL LIABILITIES AND STOCKHOLDERS' EQUITY | $14.3M | $21.6M | |
| Preferred stock, par value | $0.00 | $0.00 | |
| Preferred stock, shares authorized | 10.0M shares | 10.0M shares | |
| Preferred stock, shares issued | 0 shares | 0 shares | |
| Preferred stock, shares outstanding | 0 shares | 0 shares | |
| Common stock, par value | $0.00 | $0.00 | $0.00 |
| Common stock, shares authorized | 800.0M shares | 800.0M shares | |
| Common stock, shares issued | 7.5M shares | 1.9M shares | 136.1K shares |
| Common stock, shares outstanding | 7.5M shares | 1.9M shares |
Cash flow is reported year to date, not quarter by quarter, so there are no separate quarterly figures.
Every line of the cash flow in the latest annual report, as filed.2
| Period ending | 2026-06-30 | 2025-06-30 |
|---|---|---|
| Net loss | -$22.1M | -$17.5M |
| Amortization of intangible assets | $178.3K | $229.4K |
| Stock based compensation - restricted stock units and restricted shares | $589.7K | $1.2M |
| Stock based compensation expense - stock options | $2.3M | $1.2M |
| Stock based compensation expense - issuance of common stock for services rendered | $73.7K | |
| Amortization of financing costs | $11.8K | |
| Accretion of unearned loan discount | $111.2K | |
| Accretion of loan premium | $25.8K | |
| Non-cash lease expense from right-of-use asset | $77.1K | $67.1K |
| Change in fair value of derivative liabilities | -$3.8K | |
| Grant receivable | -$47.4K | -$2.1M |
| Prepaid and other current assets | -$1.5M | -$845.5K |
| Accounts payable and accrued expenses | $1.5M | -$1.4M |
| Operating lease liability | -$74.5K | -$60.3K |
| Net cash used in operating activities | -$19.0M | -$19.0M |
| Net proceeds from issuance of common stock | $10.5M | $15.7M |
| Proceeds from exercise of warrants | $2.9M | |
| Payment of loan premium | -$850.0K | |
| Payment of note payable | -$5.0M | |
| Net cash provided by financing activities | $10.5M | $12.7M |
| Net change in cash and cash equivalents | -$8.6M | -$6.3M |
| Cash paid for interest | $17.9K | $183.9K |
| Deemed dividend for ratchet adjustment to warrants | $43.5K | $369.5K |
Former names
- NANOANTIBIOTICS, INC.Jul 2, 2013 to Jul 22, 20163
Recent filings
- Sep 28, 2026DEF 14A
- Sep 14, 2026424B5
- Sep 14, 20268-K CURRENT REPORT
- Sep 3, 2026SCHEDULE 13G
- Aug 28, 20264
- Aug 28, 20264
- Aug 28, 20264
- Aug 28, 20264
- Aug 19, 2026SCHEDULE 13G
- Aug 14, 2026S-1/A FORM S-1 AMENDMENT NO.3
- Aug 13, 202610-K FORM 10-K FOR PERIOD ENDED JUNE 30, 2026
- Aug 7, 2026FWP FREE WRITING PROSPECTUS
- Aug 7, 2026SCHEDULE 13G
- Aug 7, 2026SCHEDULE 13G/A
- Aug 6, 20268-K CURRENT REPORT
Every filing from the last three years, summarized. The full record is on SEC EDGAR.1
Sources
The numbers on this page point here. Each one links to the record it came from.
- 1SEC EDGARBIOVIE INC. filings on SEC EDGAR
- 2SEC EDGARBIOVIE INC. 10-K for fiscal 2026
- 3SEC EDGARBIOVIE INC. filings on SEC EDGAR
- 4SEC EDGARBIOVIE INC. 10-K for fiscal 2019
- 5SEC EDGARBIOVIE INC. 10-K for fiscal 2020
- 6SEC EDGARBIOVIE INC. 10-K for fiscal 2021
- 7SEC EDGARBIOVIE INC. 10-K for fiscal 2022
- 8SEC EDGARBIOVIE INC. 10-K for fiscal 2023
- 9SEC EDGARBIOVIE INC. 10-K for fiscal 2024
- 10SEC EDGARBIOVIE INC. 10-Q for fiscal 2025
- 11SEC EDGARBIOVIE INC. 10-Q for fiscal 2026